Stock NUVL NUVALENT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Nuvalent, Inc.

Equities

NUVL

US6707031075

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
70.88 USD -2.42% Intraday chart for Nuvalent, Inc. +8.25% -3.68%
May. 17 Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing MT
May. 16 Nuvalent Gets FDA Breakthrough Therapy Designation for Lung-Cancer Treatment DJ

Evolution of the average Target Price on Nuvalent, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ea70669f9.yAtSSV9gklrklS0jJbtEPX9-YYfsdP5u4NjUienxP5w.h1wnMS8V5Q6I90ZkXIwsWjgPD8aYTc02sJGS5oijXt2nSBsubDrDKLfBXg~ef97800cc6e64eb260465e3e08e287ff

Analyst Recommendations on Nuvalent, Inc.

Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing MT
Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing MT
Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing MT
Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing MT
Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target MT
Nuvalent Insider Sold Shares Worth $2,566,479, According to a Recent SEC Filing MT
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing MT
Leerink Partners Upgrades Nuvalent to Outperform From Market Perform, Raises Price Target to $110 From $69 MT
Nuvalent Insider Sold Shares Worth $1,550,229, According to a Recent SEC Filing MT
BMO Capital Raises Price Target on Nuvalent to $102 From $93, Maintains Outperform Rating MT
Baird Initiates Nuvalent With Outperform Rating, Price Target is $105 MT
Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating MT
Wedbush Raises Nuvalent's PT to $82 From $74 After Announced 3-Year Plan to Place At Least One Lead Asset on Market by 2026; Keeps Outperform Rating MT
BMO Capital Adjusts Nuvalent Price Target to $79 From $73, Maintains Outperform Rating MT
Wedbush Raises Nuvalent Price Target to $74 From $65, Maintains Outperform Rating MT
JPMorgan Adjusts Price Target on Nuvalent to $68 From $51, Maintains Overweight Rating MT
BMO Capital Adjusts Price Target on Nuvalent to $73 From $52, Keeps Outperform Rating MT
Wedbush Raises Nuvalent's PT to $65 From $53 After Positive Phase 1 Trial Data on NVL-655 in Advanced ALK-Positive Lung Cancer; Keeps Outperform Rating MT
Nuvalent Shares Rise After Stifel Starts Coverage With Buy Rating MT
Stifel Initiates Nuvalent With Buy Rating MT
SVB Securities Initiates Nuvalent With Market Perform Rating, $42 Price Target MT
Guggenheim Starts Nuvalent at Buy With $56 Price Target MT
JPMorgan Chase Raises Price Target on Nuvalent to $48 From $37, Maintains Overweight Rating MT
Wedbush Raises Nuvalent's Price Target to $53 From $40, Outperform Rating Kept MT
Wedbush Lifts Nuvalent's Price Target to $40 From $39, Notes Progress Across Pipeline, 'Strong' Balance Sheet; Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
70.88 USD
Average target price
99.67 USD
Spread / Average Target
+40.61%
High Price Target
110 USD
Spread / Highest target
+55.19%
Low Price Target
87 USD
Spread / Lowest Target
+22.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nuvalent, Inc.

Jefferies & Co.
Leerink Partners
BMO Capital
Baird
Wedbush
JPMorgan Chase
Stifel Nicolaus
SVB Securities LLC
Guggenheim
Piper Sandler
Cowen

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NUVL Stock
  4. Consensus Nuvalent, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW